Immune Cell Trafficking

B01

Immune regulation at the CNS barriers and in the CNS:
role of immune cell trafficking

Univ.-Prof. Dr. rer. nat. Nicholas Schwab
Klinik für Neurologie mit Institut für Translationale Neurologie
Münster

Prof. Dr. med. Alexander Zarbock
Klinik für Anästhesiologie und Intensivmedizin
Münster

 

B03

Molecular mechanisms and sites of action of the gelatinases in
autoimmune CNS inflamma-tion: do MMP-2/-9 contribute to meningeal inflammation and secondary cortical damage?

Univ.-Prof. Dr. rer. nat. Lydia Sorokin
Institut für Physiologische Chemie und Pathobiochemie
Münster

Priv.-Doz. Dr. med. Gerd Meyer zu Hörste
Klinik für Neurologie mit Institut für Translationale Neurologie
Münster

 

B15

Spatiotemporal effects of IL-4 and designed novel compounds on CNS repair during neuroinflammation

Dr. rer. nat. Christina Francisca Vogelaar
Klinik für Neurologie
Mainz

Univ.-Prof. Dr. med. Frauke Zipp
Klinik für Neurologie, Forschungszentrum Immuntherapie
Mainz

News

Tue, 14/12/2021
Save the date: 2nd Inflammation & Imaging Symposium
Münster. Save the date: 12-14 September 2022! We cordially invite you to join this international symposium, jointly organized by the research networks CRC 1450, CRC 1009, CRC 1348, CRU 342, CRC/TR 128 and the Cells in Motion Interfaculty Centre at the University of Münster. At the same time, we will officially open the new research […]...more
Mon, 09/08/2021
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
A close interaction between gut immune responses and distant organ-specific autoimmunity including the CNS in multiple sclerosis has been established in recent years. This so-called gut-CNS axis can be shaped by dietary factors, either directly or via indirect modulation of the gut microbiome and its metabolites. Here, SFB 128 PI Luisa Klotz and colleagues report […]...more
Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more